YOLFTbeta
vTv Therapeutics Inc

vTv Therapeutics Inc

VTVT · NASDAQ · Healthcare / Biotechnology

19.69USD-1.00 (-4.83%)

Price History

Full chart

Market Stats

Previous Close20.69
Open20.81
Day Range19.32 – 20.81
52-Week Range19.50 – 44.00
Volume17.40K
Market Cap119.45M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.75
Dividend Yield0.00%
Beta0.28
50-Day Avg32.28
200-Day Avg34.60

About

vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases. It has a license agreement Newsoara Biopharma Co., Ltd. to develop and commercialize phosphodiesterase type 4 inhibitors program. vTv Therapeutics Inc. was incorporated in 2015 and is headquartered in High Point, North Carolina.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Paul J. Sekhri
  • Employees26
  • Headquarters3980 Premier Drive, High Point, NC, United States, 27265, USA
  • Websitehttps://vtvtherapeutics.com

Leadership

  • Mr. Paul J. SekhriCEO, President & Chairman of the Board · b. 1958
  • Dr. Michael Steven Tung M.B.A., M.D.Executive VP & CFO · b. 1974
  • Mr. Barry K. BrownChief Accounting Officer · b. 1961
  • Dr. Carmen Valcarce Ph.D.Chief Scientific Officer & Executive VP
  • Ms. Elizabeth M. KeileyExecutive VP & General Counsel · b. 1966
  • Mr. Richard S. NelsonExecutive VP of Corporate Development & Director · b. 1970
  • Dr. Thomas Strack M.D., Ph.D.Chief Medical Officer
  • Mr. Martin LafontaineChief Commercial Officer

Financials

Income Statement

Currency: USD2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue976.00K1.55M519.00K634.00K291.00K12.43M2.76M6.41M4.00M2.02M9.00K1.02M0
Growth (%)-+58.71%-66.49%+22.16%-54.10%+4172.85%-77.77%+132.05%-37.56%-49.61%-99.55%+11200.00%-100.00%
Cost of Revenue25.43M18.73M29.58M45.75M39.64M23.04M15.12M11.02M89.00K92.00K90.00K89.00K16.00K
Gross Profit-24.46M-17.18M519.00K-45.11M-39.35M-10.60M-12.36M-4.60M4.00M2.02M-90.00K1.02M-16.00K
Gross Margin-2505.94%-1109.10%100.00%-7115.77%-13521.99%-85.26%-447.00%-71.73%100.00%100.00%-1000.00%100.00%-
Operating Expense11.38M11.72M38.66M9.91M11.33M9.22M8.54M7.25M25.67M24.56M25.41M25.20M32.79M
Operating Income-35.83M-28.90M-38.14M-55.02M-50.68M-19.82M-20.89M-11.85M-21.66M-22.54M-25.50M-24.18M-32.81M
Operating Margin-3671.41%-1865.53%-7349.13%-8678.23%-17416.49%-159.43%-755.86%-184.78%-540.87%-1116.95%-283355.56%-2377.58%-
EBITDA-35.30M-29.23M-37.64M-54.69M-50.56M-20.14M-19.97M-12.02M-17.52M-24.77M-25.86M-22.52M-31.06M
EBITDA Margin-3616.29%-1886.89%-7252.60%-8626.18%-17373.88%-161.95%-722.58%-187.34%-437.33%-1227.25%-287366.67%-2213.96%-
Net Income-48.20M-36.10M-27.50M-16.35M-16.14M-7.91M-21.94M-8.50M-12.99M-19.16M-20.25M-18.46M-26.97M
Net Income Margin-4938.83%-2330.60%-5298.27%-2579.18%-5547.77%-63.62%-793.70%-132.51%-324.27%-949.65%-225000.00%-1815.34%-
R&D25.43M18.73M29.58M45.75M39.64M23.04M15.12M11.02M13.32M12.36M13.60M11.55M17.86M
R&D as % of Total Revenue2605.94%1209.10%5700.19%7215.77%13621.99%185.26%547.00%171.73%332.68%612.34%151055.56%1135.30%-
Interest Expense11.82M6.01M1.74M398.00K3.09M3.29M1.83M692.00K12.00K15.00K13.00K06.00K
Interest Expense % of Total Revenue1211.27%387.93%334.30%62.78%1062.54%26.46%66.10%10.79%0.30%0.74%144.44%0.00%-

Balance Sheet

Currency: USD2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets15.50M12.95M91.53M54.49M27.92M8.56M9.27M14.79M25.47M33.24M11.02M38.27M89.90M
Total Liabilities319.24M511.76M169.50M145.44M178.96M91.41M18.11M11.00M10.25M27.40M29.57M23.96M25.46M
Total Equity-303.73M-498.81M-77.97M-90.94M-151.05M-82.85M-49.02M-80.10M-9.74M-10.74M-24.68M12.20M64.44M
Cash1.09M1.38M88.00M51.51M11.76M1.68M1.78M5.75M13.41M12.13M9.45M36.75M88.93M
Total Debt83.17M36.17M-19.41M19.59M15.71M7.11M915.00K932.00K716.00K529.00K169.00K-
Net Debt82.08M34.78M-88.00M-40.45M7.83M14.03M5.34M-4.83M-12.48M-11.41M-8.92M-36.58M-88.93M

Cash Flow

Currency: USD2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-41.68M-30.78M-36.95M-48.21M-44.56M-26.86M-23.02M-18.00M-19.31M-15.25M-19.08M-25.31M-25.25M
Investing Cash Flow-156.00K161.00K-79.00K-83.00K-25.00K7.00K242.00K-21.00K-21.00K-21.00K4.40M--
Financing Cash Flow40.80M30.91M123.64M11.79M7.50M16.61M22.87M19.47M26.98M13.98M12.00M52.61M77.44M
Capital Expenditure181.00K33.00K104.00K87.00K57.00K5.00K70.00K21.00K21.00K21.00K000
Free Cash Flow-41.87M-30.81M-37.05M-48.30M-44.62M-26.86M-23.09M-18.00M-19.31M-15.27M-19.08M-25.31M-25.25M
Dividends Paid--000-992.00K------
FCF to OCF100.43%100.11%100.28%100.18%100.13%100.02%100.30%100.00%100.00%100.14%100.00%100.00%100.00%
Dividend Paid to FCF--0.00%0.00%0.00%--4.30%------

Earnings

Report DateSep 14, 2015Nov 12, 2015Mar 1, 2016May 12, 2016Aug 2, 2016Nov 2, 2016Feb 24, 2017May 3, 2017Aug 2, 2017Nov 1, 2017Feb 27, 2018May 15, 2018Aug 3, 2018Nov 8, 2018Feb 26, 2019May 1, 2019Jul 31, 2019Oct 30, 2019Feb 20, 2020May 7, 2020Aug 3, 2020Nov 5, 2020Feb 24, 2021May 5, 2021Aug 4, 2021Nov 9, 2021Mar 29, 2022May 12, 2022Aug 15, 2022Nov 10, 2022Mar 6, 2023May 11, 2023Aug 11, 2023Nov 9, 2023Mar 13, 2024May 9, 2024Aug 8, 2024Nov 12, 2024Mar 11, 2025May 15, 2025Aug 14, 2025Nov 6, 2025Dec 31, 2025May 13, 2026Aug 6, 2026Nov 5, 2026
EPS Estimate-1.03-15.60-1.26-21.60-23.20-16.80-0.28-17.60-18.00-15.80-16.60-16.40-16.00-4.80-4.40-0.24-6.40-6.40-0.09-4.00-3.80-4.20-0.05-2.40-2.80-2.80-0.07-3.20-4.00-1.80-2.40-0.09-0.07-0.08-0.07---3.60-0.87-0.73-0.82-0.98-1.090.21-0.75-1.07
EPS Actual-1.12-19.60-0.35-16.80-18.80-16.40-0.42-17.60-16.40-15.20-17.60-12.00-12.40-2.40-2.00-0.09-3.60-7.42-0.13-4.40-2.80-1.200.02-3.20-0.40-0.80-0.11-4.00-1.60-2.00-2.40-0.06-0.07-3.20-1.67-1.17-0.81-0.88-0.55-0.77-0.92-1.08-0.581.65-1.05-
Surprise-8.74%-25.64%72.22%22.22%18.97%2.38%-50.00%0.00%8.89%3.80%-6.02%26.83%22.50%50.00%54.55%62.50%43.75%-15.94%-44.44%-10.00%26.32%71.43%140.00%-33.33%85.71%71.43%-57.14%-25.00%60.00%-11.11%0.00%33.33%0.00%-3900.00%-2285.71%--75.56%36.55%-5.48%-12.20%-10.20%46.69%685.71%-40.00%-
TimingAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hours-

Key Statistics & Ratios

Market Cap119.45M
Enterprise Value22.77M
Trailing P/E0.00
Forward P/E0.00
PEG Ratio0.00
Price / Sales3.24
Price / Book1.54
EPS-0.75
Book Value6.34
Revenue (TTM)36.84M
Gross Profit (TTM)8.16M
EBITDA-9.24M
Profit Margin-12.91%
Operating Margin-25.11%
Return on Equity-15.80%
Return on Assets-10.14%
Shares Outstanding3.95M
Shares Float2.16M
Beta0.28
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 2 analystsTarget 54.71
  • Strong Buy
    1
  • Buy
    1

Ownership Breakdown

Institutions
40.75%
Insiders
38.83%
Retail / Other
20.42%

Top Institutional Holders

  • Samsara BioCapital, LLC
    298.50K7.55%
  • Millennium Management LLC
    269.87K6.83%
  • FMR Inc
    260.39K6.59%
  • Siren, L.L.C.
    163.00K4.12%
  • Baker Bros Advisors LP
    148.31K3.75%
  • Vanguard Capital Management, LLC
    108.92K2.75%
  • Trails Edge Capital Partners, LP
    85.19K2.15%
  • Aisling Capital Management LP
    50.00K1.26%
  • Geode Capital Management, LLC
    32.89K0.83%
  • Northern Trust Corp
    18.05K0.46%
  • Vanguard Fiduciary Trust Co
    16.13K0.41%
  • 683 Capital Management LLC
    16.00K0.40%
  • Marshall Wace Asset Management Ltd
    13.39K0.34%
  • The Goldman Sachs Group Inc
    13.35K0.34%
  • BlackRock Inc
    12.60K0.32%
  • Two Sigma Investments LLC
    11.49K0.29%
  • State Street Corp
    10.67K0.27%

Top Fund Holders

  • Fidelity Select Biotechnology
    260.39K6.59%
  • Vanguard MStar Total Stk Mkt Idx Invest
    60.76K1.54%
  • Fidelity Extended Market Index
    14.02K0.35%

Stock Splits

  • Nov 21, 20231:40